# GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

> **NCT04238936** · — · COMPLETED · sponsor: **Kanuni Sultan Suleyman Training and Research Hospital** · enrollment: 80 (actual)

## Conditions studied

- Gestational Diabetes

## Interventions

- **DIAGNOSTIC_TEST:** Serum amyloid A values
- **DIAGNOSTIC_TEST:** Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)

## Key facts

- **NCT ID:** NCT04238936
- **Lead sponsor:** Kanuni Sultan Suleyman Training and Research Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-20
- **Primary completion:** 2020-05-20
- **Final completion:** 2020-05-20
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238936, "GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04238936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*